Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCENIC trial of inhaled RVT-1601 for persistent cough in idiopathic pulmonary fibrosis
NL-OMON48040Phase 2Not yet recruiting
- Sponsor
- Respivant Sciences
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) and chronic cough comparing RVT-1601 with Placebo (2 arms). Primary endpoint: Change from baseline in 24-hour average cough count at end of treatment. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
RVT-1601
03
Conditions
idiopathic pulmonary fibrosis (IPF)chronic cough
Beyond the preview
Go deeper on NL-OMON48040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48040.